She has been a consultant for Novavax since 2011
Novavax, a clinical-stage US biopharmaceutical company focused on the development of recombinant nanoparticle vaccines and adjuvants, has appointed Cynthia Oliver as Senior Vice President of Process Development Operations.
Oliver is responsible for all process development activities, with a specific focus on the company's RSV F-protein nanoparticle, seasonal influenza and pandemic influenza vaccine candidates.
Oliver has been a Novavax consultant since 2011 where her expertise and experience have helped the company formulate and execute on critical process development strategies.
From 1993 to 2010, Oliver held a variety of positions, including Vice President, Process Biochemistry and Formulation Sciences at Medimmune, with responsibilities that included vaccines, proteins, monoclonal antibodies and small molecules, including the commercial products Synagis and FluMist.
Prior to MedImmune, she had similar responsibilities at Merck Research Laboratories, and spent a number of years working at the National Institutes of Health in the National Heart, Lung and Blood Institute.